Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Launched by ATEA PHARMACEUTICALS, INC. · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how two medications, Omeprazole and Bemnifosbuvir/Ruzasvir, interact with each other in healthy volunteers. Omeprazole is often used to reduce stomach acid, while Bemnifosbuvir/Ruzasvir is being studied for treating certain viral infections. The trial is in the early phase of research and is not yet recruiting participants.

To be eligible for this study, participants must be between 18 and 70 years old, weigh at least 50 kg, and have a body mass index (BMI) between 18.5 and 30. Participants should also agree to use effective birth control methods during the study and for 90 days afterward. However, people with certain conditions, such as hepatitis or HIV, those who abuse drugs or alcohol, or those taking other medications, will not be able to participate. If selected, participants can expect to follow specific study guidelines and provide consent to join the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.
• • Minimum body weight of 50 kg and body mass index (BMI) of 18.5-30 kg/m2.
• • Willing to comply with the study requirements and to provide written informed consent.
• Exclusion Criteria:
• • Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2.
• • Abuse of alcohol or drugs.
• • Use of other investigational drugs within 28 days of dosing.
• • Concomitant use of prescription medications, or systemic over-the-counter medications.
• • Other clinically significant medical conditions or laboratory abnormalities.